Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. - Wikidata - wikimedia - TriplyDB

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease.

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease.

http://www.wikidata.org/entity/Q34431511

about

Schnitzler's syndrome: lessons from 281 cases Tocilizumab A case of nodular sclerosis Hodgkin's lymphoma repeatedly relapsing in the context of composite plasma cell-hyaline vascular Castleman's disease: successful response to rituximab and radiotherapy Update and new approaches in the treatment of Castleman disease Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis Interleukin-6: an emerging regulator of pathological pain Emerging treatments in Castleman disease - a critical appraisal of siltuximab Discovery of Innovative Therapies for Rare Immune-Mediated Inflammatory Diseases via Off-Label Prescription of Biologics: The Case of IL-6 Receptor Blockade in Castleman's Disease Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling Interleukin-6 blockade in ocular inflammatory diseases Castleman disease in the parapharyngeal space: a case report and review of the literature KSHV: pathways to tumorigenesis and persistent infection Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma Review of siltuximab in the treatment of multicentric Castleman's disease Inflammation induced loss of skeletal muscle Interleukin-6 mediates epithelial-stromal interactions and promotes gastric tumorigenesis Structure-based virtual screening and characterization of a novel IL-6 antagonistic compound from synthetic compound database Interleukin-6 receptor-mediated activation of signal transducer and activator of transcription-3 (STAT3) promotes choroidal neovascularization TAFRO syndrome successfully treated with tocilizumab: A case report and systematic review.International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.TAFRO syndrome: New subtype of idiopathic multicentric Castleman disease.Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome.Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias Hepcidin and sports anemia In immune defense: redefining the role of the immune system in chronic disease.The relationship between pro-inflammatory cytokines and pain, appetite and fatigue in patients with advanced cancer.Early administration of IL-6RA does not prevent radiation-induced lung injury in mice Ultrasensitive Label-Free Sensing of IL-6 Based on PASE Functionalized Carbon Nanotube Micro-Arrays with RNA-Aptamers as Molecular Recognition Elements.Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer Current concepts in the diagnosis and management of cytokine release syndrome.A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab IgG4-related sclerosing disease, an emerging entity: a review of a multi-system disease IL-6 in inflammation, immunity, and disease Contribution of viral mimics of cellular genes to KSHV infection and disease.IL-6 signaling blockade increases inflammation but does not affect muscle function in the mdx mouse.Inflammation and fatigue dimensions in advanced cancer patients and cancer survivors: an explorative study.Impact of interleukin-6 in hematological malignancies.Assessment of the validity of the 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR) as a disease activity index of rheumatoid arthritis in the efficacy evaluation of 24-week treatment with tocilizumab: subanalysis of t KSHV-associated multicentric Castleman disease: A tangle of different entities requiring multitarget treatment strategies.Skewed production of IL-6 and TGFβ by cultured salivary gland epithelial cells from patients with Sjögren's syndrome

P2860

Q21195864-5CDF8318-CE5C-4E60-9660-2D1C2E9E1882 Q24655317-6BD7FC39-0E33-4615-AC94-AA610B69A9A5 Q24670564-C733362D-410C-4D40-A691-ED1A575F5F00 Q26740703-14D28C96-18EA-40A7-ACCC-AE4B8A239A12 Q26746099-78F190A3-7254-4964-B247-9A4AEEFD9E2C Q26748646-E8E98FBC-01B3-4988-A661-AF9A2A6A9D0C Q26766554-B90607B6-00CA-4B52-A821-AA3EB9524CB3 Q26772331-C0673B59-17C0-4B02-ABB4-2C617B15FE67 Q27002391-B1E4B9C4-69C4-48F2-8BFF-5F14C7AEB617 Q27011357-F7A7206B-7595-41B0-AFCB-EB3CF964C005 Q27012845-BA932253-BD12-4957-8F30-2CD87BF4EAA8 Q27026000-854BEFC1-03DF-405B-99ED-62BD4AC93362 Q27027729-1E33594D-C89B-47BA-B98E-41E7A256B5DF Q28067246-DE404B9C-C763-4E61-ACEF-23B407F6102C Q28083759-D95782D1-2CFE-44BA-AFA1-B5A0C5BACE70 Q28486177-DDB2B7E2-A7FF-4467-AFDD-DD29723BD812 Q28817043-D24BFC4C-CDA8-4AD1-B2F8-C784714C44A5 Q33285746-92D68C1A-3790-4D2E-8225-7FFF724347DB Q33430083-76CE9EBC-07A9-4D1E-A237-521C2C369EB1 Q33438403-D4E60DF9-FD70-4F04-A72C-33F58389C039 Q33438812-4E6F43A2-C797-4533-873B-73CD3C6C43B2 Q33439399-E2F74FC3-CC73-4DA3-B64F-500CDD0DCFA9 Q33559201-EB153320-ACDE-4C55-8B6B-CECF86CDE1FC Q33559763-9768B812-2D5A-4F53-B87F-2274112AB8D9 Q33721014-801DD140-D896-472F-B26A-58E365E4B5C5 Q33727960-88CA90CE-8762-4576-82C6-A9C982FE92A3 Q33828652-0BA9BA66-C90A-4DCA-A1FA-20609F52CE2A Q33844812-E140E50F-3C0B-4029-9472-1A5B6A487B05 Q33882832-A4426AB8-3E3D-4115-833F-0691DEADAFA1 Q33886879-BAE2D4AE-5C16-4FA8-AFD9-2ABA449DFA95 Q34073690-F7E6A29F-4638-4CC4-8648-55E63C423202 Q34242001-142A1193-037E-495F-A4A1-51017A199D36 Q34248105-866784EB-A9C9-478D-B0A9-AEA31F99C68C Q34303583-5BB8A365-AF8D-4E75-9631-2391A124BF55 Q34310898-01965593-8EDE-41B3-9038-AFCFB27946B1 Q34317938-446E58DD-14DA-48F7-8EA9-E5E9631B29EC Q34387624-1EC8D83D-DADD-4B70-9D1E-F790E5AF5C25 Q34394122-5B7C0647-1F12-49FD-9A25-B025A73EE52D Q34417383-B64FD77D-5B60-412B-AEC3-BFF6675E0FFC Q34464370-807FCCC4-084B-4A92-AA9C-F1F573EF01A3

P2860

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease.

http://www.wikidata.org/entity/Q34431511

description

2005 nî lūn-bûn

@nan

2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Humanized anti-interleukin-6 r ...... ulticentric Castleman disease.

@ast

Humanized anti-interleukin-6 r ...... ulticentric Castleman disease.

@en

Humanized anti-interleukin-6 r ...... ulticentric Castleman disease.

@nl

type

label

Humanized anti-interleukin-6 r ...... ulticentric Castleman disease.

@ast

Humanized anti-interleukin-6 r ...... ulticentric Castleman disease.

@en

Humanized anti-interleukin-6 r ...... ulticentric Castleman disease.

@nl

prefLabel

Humanized anti-interleukin-6 r ...... ulticentric Castleman disease.

@ast

Humanized anti-interleukin-6 r ...... ulticentric Castleman disease.

@en

Humanized anti-interleukin-6 r ...... ulticentric Castleman disease.

@nl

P1433

Q34431511-16616EAD-D805-4E77-ADF8-7FA9757A05AD

P1476

Q34431511-04F31AB8-76C7-4B8F-8D27-B99F19801F5D

P2093

Q34431511-075857FF-F385-449B-BF51-A1F19DFAA979

Q34431511-0AE6A410-4EE4-466C-BA74-CD8DDA780AC6

Q34431511-133C0438-38B4-450D-85B0-356CCC791129

Q34431511-1437024F-005F-4051-B96C-A9B0369B864B

Q34431511-1B15C105-19BE-40FD-ADF5-590C1EA8A174

Q34431511-247DA370-9C75-48DF-B619-8EECFC2B00D9

Q34431511-3080B74B-63EC-47F3-B4D8-5C99D1D4D634

Q34431511-41ABA11B-7E8C-45F3-B622-65EC26AB8E13

Q34431511-57F6E45A-01F7-47EE-B1B0-847CE6428A36

Q34431511-59E46453-10DE-4FC0-97C1-A3DB8C2A5BD2

P304

Q34431511-EA75673F-4417-40C2-8006-B38E69D82F8A

P31

Q34431511-559A6075-1F44-43DC-A74B-C84C278B2D62

P356

Q34431511-524A31EC-758F-45C8-BC37-3C58F5876A84

P407

Q34431511-ACF3922C-F008-410E-8E02-C19A9321B442

P433

Q34431511-681351D8-535F-4DC2-889C-F5D268FBF914

P478

Q34431511-F5B48A0F-B044-4506-90CD-F0D6732D34E8

P577

Q34431511-0F5C0DD1-93E2-4948-B74A-1AFB6ECE9FDF

P698

Q34431511-8690BDFA-6A43-4298-A35C-4C2CCC70A98C

P921

Q34431511-0C4E42D6-3A0F-4943-887E-A526F6E7E521

Q34431511-4bd9bfb1-ea53-44ef-9cca-96f50af14454

P356

BLOOD-2004-12-4602

P1433

P1476

Humanized anti-interleukin-6 r ...... ulticentric Castleman disease.

@en

P2093

Fumio Kodama

http://www.w3.org/2001/XMLSchema#string

Hideki Asaoku

http://www.w3.org/2001/XMLSchema#string

Hideko Nakahara

http://www.w3.org/2001/XMLSchema#string

Hirokuni Taguchi

http://www.w3.org/2001/XMLSchema#string

Katsuyuki Aozasa

http://www.w3.org/2001/XMLSchema#string

Kazuyuki Yoshizaki

http://www.w3.org/2001/XMLSchema#string

Keisuke Hagihara

http://www.w3.org/2001/XMLSchema#string

Kiyoshi Nishioka

http://www.w3.org/2001/XMLSchema#string

Masamichi Hara

http://www.w3.org/2001/XMLSchema#string

Minoru Nakamura

http://www.w3.org/2001/XMLSchema#string

P304

2627-2632

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2004-12-4602

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P577

2005-07-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15998837

http://www.w3.org/2001/XMLSchema#string

P921